[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-esophagus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-esophagus":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,126,162,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100249843","mayo-clinic-upper-digestive-disease-survey-100249843",false,"NCT02530983","Mayo Clinic Upper Digestive Disease Survey","UDD","Inclusion Criteria:\n\n* Patients undergoing or having already undergone an esophagectomy or esophageal reconstruction.","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","The Mayo Clinic Conduit Report Card Questionnaires have been created in order to have a consistent evaluation tools for patients undergoing esophageal reconstruction or treatment or patients that are experiencing an upper digestive disease in order to standardize and validate outcome measures. Data will be used to establish the validation of the questionnaires\u002Fsurvey. Data will also lead to the establishment of \"normal\" or expected scores for patients undergoing each type of esophagectomy procedure and for upper digestive diseases. Data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as well as contribute to pre-operative education.",[24,25,26,27,28,29,30,31,32],"Esophageal Neoplasms","Cancer of Esophagus","Cancer of the Esophagus","Esophageal Cancer","Esophagus Cancer","Neoplasm, Esophageal","Esophagectomy","Abnormalities, Digestive System","Digestive System Abnormalities","RECRUITING","2026-03-24",{"date":36,"type":37},"2026-03-30","ACTUAL",{"date":39,"type":37},"2015-08-15",{"date":41,"type":20},"2028-12",{"name":43,"class":44},"Mayo Clinic","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":99,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":53,"type":20},50000,"36 Months","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[57,58,59,60,61,62,63,64,25,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98],"Cancer, Metastatic","Cancer","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Ovarian Cancer","Endometrial Cancer","Testicular Cancer","Breast Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[100,101,102,103,104,105,106,107,108,109,110,111,112,113,114],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","cancer","value based care","real world data","data analytics","2025-10-25",{"date":117,"type":37},"2025-10-28",{"date":119,"type":37},"2018-01-01",{"date":121,"type":20},"2040-06",{"name":123,"class":124},"Massive Bio, Inc.","INDUSTRY",68,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":137,"phases":138,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":45},"100442434","wet-heparinized-suction-for-abdominal-cancer-100442434","NCT05041335","Wet Heparinized Suction for Abdominal Cancer","Wet Heparinized Suction: A Novel Technique to Enhance Tissue Acquisition for Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB) of Solid Abdominal Masses: A Randomized Prospective Trial","EUS Heparin","Inclusion Criteria:\n\n* Age ≥ 18 year\n* Non-pregnant Patients\n* Patients with the presence of a solid abdominal mass as seen on diagnostic imaging \\[ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)\\] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA\u002FFNB for solid pancreatic mass and did not receive a conclusive diagnosis\n* Patients with platelet count \\> 50,000\n* Patients with International Normalized Ratio (INR) \\\u003C 1.5\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant Patients\n* Patients who cannot consent for themselves\n* Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days\n* Patients with cystic abdominal masses\n* Patients with a platelet count \\\u003C 50,000\n* Patients with an INR \\> 1.5\n* Patients with a heparin or porcine allergy\n* Patients with prior heparin induced thrombocytopenia (HIT)\n* Patient's with religious aversion to porcine-containing products",true,{"count":136,"type":20},42,"INTERVENTIONAL",[139],"NA","The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or \"blood thinner\" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis.\n\nYou will be randomly assigned (like a flip of a coin) to have either the blood thinner or the salt water solution placed within the needle being used to sample your abdominal tumor and to have either a sieve used or not.\n\nYou will be one of 42 participants enrolled in this data collection study which includes 1 sites in the United States.",[59,61,25,60,58],[111,143,144,145,146,147,148,149,150,151],"esophagus","stomach","gastric","pancreas","biliary","bile","bile duct","liver","hepatic","NOT_YET_RECRUITING","2025-04-21",{"date":155,"type":37},"2025-04-22",{"date":157,"type":20},"2026-03-15",{"date":159,"type":20},"2027-01-12",{"name":161,"class":44},"H. Lee Moffitt Cancer Center and Research Institute",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100397450","circulating-biomarkers-for-individualized-surgical-therapy-in-gastroesophageal-cancer---phase-1-100397450","NCT04455282","CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1","CIRCULATE1","Inclusion Criteria:\n\n* histologically proven adenocarcinoma of the GEJ type I and II, resectable, non-metastatic tumor\n* age ≥18\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2,\n* American Society of Anesthesiologists (ASA) \\\u003C 4.\n* pre-treatment stage cT1N+ M0 or cT2-4a N0\u002FN+, M0 GEJ type I and II adenocarcinomas can be included. In case of stage cT4a, curative resectability has to be explicitly verified by the local surgical investigator prior inclusion.\n* Written informed consent and the ability to understand the nature of the study and the study-related procedures and to comply with them has to be ensured.\n\nExclusion Criteria:\n\n* tumors of squamous, adenosquamous or other non-adenocarcinoma histology\n* patients with inoperable or metastatic GEJ type I and II adenocarcinoma, GEJ type I and II adenocarcinoma staged cT1N0 and cT4b, GEJ type I and II cT4a evaluated as not curatively resectable by the local surgical investigator\n* unsigned informed consent",{"count":170,"type":20},100,"This is an exploratory observational biomarker study in approximately 100 eligible patients with resectable adenocarcinomas of the esophagus and gastro- esophageal junction (GEJ) type I-II (GEAC) to investigate the difference deletion frequency of circulating tumor cells (CTCs) between peripheral veins and tumor-draining veins (primary endpoint), prognostic value, relevance of a set of two additional blood-based biomarkers analyzed from a single blood sampling tube (secondary endpoints). The underlying hypothesis is that the biomarker alone or in combination improve preoperative staging and help to identify patients at risk for metastasis. This should enable a better stratification of GEAC patients to neo-adjuvant treatment, (intensified) peri-operative treatment, or even surgery alone, in selected cases. The data of the CIRCULATE study shall be used design subsequent studies testing the predictive role of these biomarkers for surgical management. Patients will provide blood samples and lymphatic fluid during the operation and annual blood samples during clinical follow up of 5 years.",[25,173],"Esophagogastric Junction Disorder",[175,176,177,178],"Circulating Biomarkers","CTC","tdEVs","ctDNA","2024-03-07",{"date":181,"type":37},"2024-03-08",{"date":183,"type":37},"2021-02-01",{"date":185,"type":20},"2028-01-30",{"name":187,"class":44},"Heinrich-Heine University, Duesseldorf",2,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":45},"100430558","surgery-as-needed-for-oesophageal-cancer---2-100430558","NCT04886635","Surgery As Needed for Oesophageal Cancer - 2","A Prospective Cohort Study on Active Surveillance After Neoadjuvant Chemoradiation for Oesophageal Cancer: SANO-2 Study","SANO-2","Inclusion Criteria:\n\n* Operable patients who are planned to undergo or who recently underwent neoadjuvant chemoradiotherapy according to CROSS followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophago-gastric junction\n* Age ≥18\n* Written, voluntary, informed consent.\n\nExclusion Criteria:\n\n* Non-FDG-avid tumour at baseline PET-CT scan\n* Initial treatment with endoscopic resection\n* Patients who underwent of who are planned to undergo definitive chemoradiotherapy\n* Language difficulty, dementia or altered mental status prohibiting the understanding and giving of informed consent.",{"count":198,"type":20},360,"A prospective cohort study on active surveillance after neoadjuvant chemoradiation for oesophageal cancer: SANO-2 study.",[25],"2024-02-16",{"date":203,"type":37},"2024-02-20",{"date":205,"type":37},"2021-03-09",{"date":207,"type":20},"2029-01-01",{"name":209,"class":44},"Bas P. L. Wijnhoven"]